NASDAQ: OBXObsidian Therapeutics Inc Stock
$32.90-2.10 (-6%)
Updated Aug 11, 2026
OBX Price
$32.90
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$16.00
52 Week High
$49.97
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.06
Operating Cash Flow
N/A
Beta
36.64
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OBX Overview
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OBX's potential to beat the market
- OBX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OBX
RankedUnranked of 465
RankedUnranked of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.77 | A | |
| $10.95 | A | |
| $111.86 | A |
Be the first to know about important OBX news, forecast changes, insider trades & much more!
OBX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OBX's short-term assets ($64.04M) exceed its short-term liabilities ($15.23M)
Short-term Liabilities Financials
OBX's short-term assets ($64.04M) exceed its long-term liabilities ($1.08M)
Long-term Liabilities Financials
OBX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more OBX due diligence checks available for Premium users.
Valuation
OBX's financial health
Profit margin
Revenue
$0.0
Net Income
-$19.6M
Profit Margin
0%
Assets to liabilities
Assets
$70.1M
Liabilities
$16.3M
Debt to equity
-0.06
OBX's short-term assets ($64.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OBX's short-term assets ($64.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OBX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.0M
Investing
$8.0M
Financing
$47.0k
Obsidian Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.